We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

78 hedge funds and large institutions have $546M invested in Revance Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 28 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more call options, than puts

Call options by funds: $687K | Put options by funds: $349K

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

1% more capital invested

Capital invested by funds: $540M → $546M (+$6.08M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 81 → 78 (-3)

18% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 28

Holders
78
Holders Change
-3
Holders Change %
-3.7%
% of All Funds
1.94%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
23
Reduced
28
Closed
9
Calls
$687K
Puts
$349K
Net Calls
+$338K
Net Calls Change
-$26K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$42M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.46M
3
Goldman Sachs
Goldman Sachs
New York
+$2.9M
4
State Street
State Street
Massachusetts
+$2.56M
5
PC
PointState Capital
New York
+$2.08M

Top Sellers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
-$6.1M
2
Bank of New York Mellon
Bank of New York Mellon
New York
-$2.55M
3
ACH
ArrowMark Colorado Holdings
Colorado
-$1.89M
4
CPIM
Columbia Partners Investment Management
Virginia
-$1.51M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$1.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
26
Vivo Capital
California
$1.61M – – –
TCIM
27
TIAA CREF Investment Management
New York
$1.57M -$49.6K -2,413 -3%
GIP
28
Granite Investment Partners
California
$1.48M -$61.1K -2,976 -4%
Wells Fargo
29
Wells Fargo
California
$1.48M -$301K -14,632 -17%
RCAMU
30
Rothschild & Co Asset Management US
Connecticut
$1.18M -$85.8K -4,176 -7%
USAA
31
United Services Automobile Association
Texas
$1.14M -$45.2K -2,200 -4%
Allianz Asset Management
32
Allianz Asset Management
Germany
$1.05M +$1.04M +50,613 New
California State Teachers Retirement System (CalSTRS)
33
California State Teachers Retirement System (CalSTRS)
California
$838K -$37K -1,800 -4%
PAM
34
Paradigm Asset Management
New York
$743K +$733K +35,700 New
Victory Capital Management
35
Victory Capital Management
Texas
$739K +$730K +35,525 New
Acadian Asset Management
36
Acadian Asset Management
Massachusetts
$735K +$726K +35,338 New
TA
37
Teachers Advisors
New York
$701K -$493 -24 -0.1%
Swiss National Bank
38
Swiss National Bank
Switzerland
$683K +$43.1K +2,100 +7%
PPA
39
Parametric Portfolio Associates
Washington
$570K +$31.3K +1,524 +6%
NFA
40
Nationwide Fund Advisors
Ohio
$550K -$72.9K -3,547 -12%
State of New Jersey Common Pension Fund D
41
State of New Jersey Common Pension Fund D
New Jersey
$541K – – –
CM
42
Crestline Management
Texas
$520K +$514K +25,000 New
AA
43
ALPS Advisors
Colorado
$510K -$59K -2,873 -10%
AllianceBernstein
44
AllianceBernstein
Tennessee
$499K -$78.1K -3,800 -14%
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$485K +$90.4K +4,401 +23%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$477K +$40.1K +1,952 +9%
Millennium Management
47
Millennium Management
New York
$472K -$571K -27,797 -55%
Ameriprise
48
Ameriprise
Minnesota
$472K – – –
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$419K -$12.5K -609 -3%
Federated Hermes
50
Federated Hermes
Pennsylvania
$417K +$1.05K +51 +0.3%
1
2
3 4

RVNC Hedge Fund Activity: Q1 2017 in Review

78 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2017, worth a combined $546M — up 1.1% from $540M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new RVNC positions and 9 closed out — a net gain of 2 holders — while 23 added to existing stakes and 28 trimmed.

The largest buyer was BlackRock, adding an estimated $42M. The largest seller was Franklin Resources, cutting an estimated $6.1M.

  • 78 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2017, down from 81 in Q4 2016.
  • Funds reported $546M of Revance Therapeutics, Inc. stock for Q1 2017, up 1.1% quarter-over-quarter.
  • 11 funds opened new Revance Therapeutics, Inc. positions in Q1 2017 and 9 closed out, a net change of +2 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q1 2017 was BlackRock, an estimated $42M added.
  • The largest Revance Therapeutics, Inc. seller in Q1 2017 was Franklin Resources, an estimated $6.1M sold.

Based on aggregated 13F filings for Q1 2017.